{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Epithelial+Ovarian",
    "query": {
      "condition": "Advanced Epithelial Ovarian"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 401,
    "total_pages": 41,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Epithelial+Ovarian&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T00:11:33.622Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00413322",
      "title": "Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tumor"
      ],
      "interventions": [
        {
          "name": "belinostat",
          "type": "DRUG"
        },
        {
          "name": "5-Fluorouracil (5-FU)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Valerio Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2005-09",
      "completion_date": "2008-06",
      "has_results": false,
      "last_update_posted_date": "2015-07-08",
      "last_synced_at": "2026-05-22T00:11:33.622Z",
      "location_count": 3,
      "location_summary": "Scottsdale, Arizona • Omaha, Nebraska • Portsmouth, New Hampshire",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Portsmouth",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00413322"
    },
    {
      "nct_id": "NCT01975831",
      "title": "A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Ovarian Cancer",
        "Colorectal Cancer",
        "Cervical Cancer",
        "Renal Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Tremelimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ludwig Institute for Cancer Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 104,
      "start_date": "2013-12-19",
      "completion_date": "2021-07-02",
      "has_results": true,
      "last_update_posted_date": "2022-10-12",
      "last_synced_at": "2026-05-22T00:11:33.622Z",
      "location_count": 6,
      "location_summary": "New Haven, Connecticut • Boston, Massachusetts • Buffalo, New York + 3 more",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01975831"
    },
    {
      "nct_id": "NCT04881045",
      "title": "Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "Squamous Cell Carcinoma of the Head and Neck",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "PF-07257876",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2021-08-18",
      "completion_date": "2023-10-24",
      "has_results": false,
      "last_update_posted_date": "2024-04-03",
      "last_synced_at": "2026-05-22T00:11:33.622Z",
      "location_count": 39,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 25 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Rogers",
          "state": "Arkansas"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04881045"
    },
    {
      "nct_id": "NCT02611024",
      "title": "Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Glioblastoma",
        "Soft Tissue Sarcoma (Excluding GIST)",
        "Endometrial Carcinoma",
        "Epithelial Ovarian Carcinoma",
        "Mesothelioma",
        "Gastroenteropancreatic Neuroendocrine Tumor",
        "SCLC",
        "Gastric Carcinoma",
        "Pancreatic Adenocarcinoma",
        "Colorectal Carcinoma",
        "Neuroendocrine Tumors"
      ],
      "interventions": [
        {
          "name": "Lurbinectedin",
          "type": "DRUG"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PharmaMar",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 316,
      "start_date": "2016-05-06",
      "completion_date": "2025-07-01",
      "has_results": false,
      "last_update_posted_date": "2025-07-09",
      "last_synced_at": "2026-05-22T00:11:33.622Z",
      "location_count": 4,
      "location_summary": "Santa Monica, California • Boston, Massachusetts • Houston, Texas",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02611024"
    },
    {
      "nct_id": "NCT03621982",
      "title": "Study of ADCT-301 in Patients With Selected Advanced Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Head and Neck Cancer Squamous Cell Carcinoma",
        "Non-small Cell Lung Cancer",
        "Gastric Cancer",
        "Esophageal Cancer",
        "Pancreas Cancer",
        "Bladder Cancer",
        "Renal Cell Carcinoma",
        "Melanoma",
        "Triple-negative Breast Cancer",
        "Ovarian Cancer",
        "Colo-rectal Cancer",
        "Fallopian Tube Cancer"
      ],
      "interventions": [
        {
          "name": "ADCT-301",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "ADC Therapeutics S.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2018-11-09",
      "completion_date": "2022-12-14",
      "has_results": true,
      "last_update_posted_date": "2024-06-13",
      "last_synced_at": "2026-05-22T00:11:33.622Z",
      "location_count": 5,
      "location_summary": "Palo Alto, California • New Haven, Connecticut • Portland, Oregon + 2 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03621982"
    },
    {
      "nct_id": "NCT04440943",
      "title": "A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer",
        "Breast Cancer",
        "Gastric Cancer",
        "Renal Cell Carcinoma",
        "Ovarian Cancer",
        "Primary Peritoneal Carcinoma",
        "Fallopian Tube Cancer",
        "Cholangiocarcinoma",
        "Bladder Urothelial Carcinoma",
        "MSI-H Colorectal Cancer",
        "Esophageal Cancer",
        "Hepatic Cancer",
        "Head and Neck Cancer",
        "Other Solid Tumors"
      ],
      "interventions": [
        {
          "name": "CDX-527",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celldex Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2020-08-04",
      "completion_date": "2023-04-06",
      "has_results": false,
      "last_update_posted_date": "2023-06-18",
      "last_synced_at": "2026-05-22T00:11:33.622Z",
      "location_count": 5,
      "location_summary": "Atlanta, Georgia • Chicago, Illinois • Omaha, Nebraska + 2 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04440943"
    },
    {
      "nct_id": "NCT03907852",
      "title": "Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Mesothelioma",
        "Mesothelioma, Malignant",
        "Mesothelioma; Pleura",
        "Mesotheliomas Pleural",
        "Mesothelioma Peritoneum",
        "Cholangiocarcinoma",
        "Cholangiocarcinoma Recurrent",
        "Ovarian Cancer",
        "Non Small Cell Lung Cancer",
        "Non Small Cell Lung Cancer Metastatic",
        "High Grade Ovarian Serous Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "gavo-cel",
          "type": "BIOLOGICAL"
        },
        {
          "name": "fludarabine",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Ipilimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "TCR2 Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 57,
      "start_date": "2019-04-15",
      "completion_date": "2028-11-02",
      "has_results": false,
      "last_update_posted_date": "2025-08-27",
      "last_synced_at": "2026-05-22T00:11:33.622Z",
      "location_count": 10,
      "location_summary": "San Francisco, California • Miami, Florida • Chicago, Illinois + 6 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03907852"
    },
    {
      "nct_id": "NCT01175343",
      "title": "RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma",
        "Stage IV Fallopian Tube Cancer",
        "Stage IV Ovarian Cancer",
        "Stage IV Primary Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "Gamma-Secretase Inhibitor RO4929097",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 45,
      "start_date": "2010-07",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2017-05-24",
      "last_synced_at": "2026-05-22T00:11:33.622Z",
      "location_count": 6,
      "location_summary": "Beverly Hills, California • Duarte, California • Los Angeles, California + 3 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01175343"
    },
    {
      "nct_id": "NCT00583622",
      "title": "Bevacizumab Plus Gemcitabine, Docetaxel, Melphalan, and Carboplatin in Ovarian Cancer Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Stem Cell Transplant",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 70 Years · Female only"
      },
      "enrollment_count": 13,
      "start_date": "2007-12",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2013-05-21",
      "last_synced_at": "2026-05-22T00:11:33.622Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00583622"
    },
    {
      "nct_id": "NCT00635193",
      "title": "Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer, Primary Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "M200 (Volociximab)",
          "type": "DRUG"
        },
        {
          "name": "Liposomal Doxorubicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie (prior sponsor, Abbott)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 138,
      "start_date": "2007-07",
      "completion_date": "2009-10",
      "has_results": false,
      "last_update_posted_date": "2013-01-18",
      "last_synced_at": "2026-05-22T00:11:33.622Z",
      "location_count": 14,
      "location_summary": "Anaheim, California • Redondo Beach, California • Sunrise, Florida + 11 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Redondo Beach",
          "state": "California"
        },
        {
          "city": "Sunrise",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Savannah",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00635193"
    }
  ]
}